TAPP is once again sounding the alarm on the possible misuse of the Bayh-Dole Act by the Biden Administration to impose price controls. A U.S. Department of Health and Human Services (HHS) and Department of Commerce (DOC) working group is expected to release recommendations on the implementation of the Bayh-Dole Act’s “march-in” provision soon.
Read MoreAs TAPP has said, the Inflation Reduction Act is a threat to the American pharmaceutical industry and patients everywhere. A recent article from The Wall Street Journal highlights the damage done to an American biotech company, Seagan Inc., as it was forced to shut down a successful cancer treatment because of this legislation.
Read MoreOn October 31, the U.S. Government Accountability Office released a report, “Sugar Program: Alternative Methods for Implementing Import Restrictions Could Increase Effectiveness.”
Read MoreThe Trade Alliance to Promote Prosperity joined more than 40 organizations in writing to Congress and urging the members to repeal the prescription drug price controls in the IRA.
Read MoreThe Trade Alliance to Promote Prosperity today wrote to U.S. Senator Marsha Blackburn to thank her for her planned resolution recognizing the importance of the U.S.-Israel Free Trade Agreement.
Read MoreThe Trade Alliance to Promote Prosperity wrote to the U.S. Senate Committee on Health, Education, Labor, and Pensions in advance of a full committee meeting to consider the nomination of Monica Bertagnolli to lead the National Institutes of Health, urging the committee to reject anti-competitive and anti-innovation schemes that might arise during the discussions…
Read MoreLast week, a number of judges, former government officials, and scholars who are experts in patent law, healthcare policy, or both, wrote a letter to U.S. legislators in an effort to stop the government from imposing price controls on patented drugs.
Read MoreTAPP and 11 other organizations recently signed a letter challenging the Biden Administration on its mismanagement of the No Surprises Act.
Read MoreThe Inflation Reduction Act and its price controls continue to damage the pharmaceutical industry as they limit innovation and patient access. The House Energy and Commerce Committee recently announced an oversight hearing will be held this coming Wednesday titled, “At What Cost: Oversight of How the IRA's Price Setting Scheme Means Fewer Cures for Patients.”
Read MorePharmacy Benefit Managers have been spreading misleading information, claiming that efforts to prevent their dishonest practices and enhance accountability equate to excessive government involvement in healthcare.
Read MoreAs TAPP has stated in the past, the Inflation Reduction Act and its price controls are damaging the pharmaceutical industry and preventing drug research. Now that this horrible piece of legislation is a year old, let's recap the many negative aspects of it.
Read MoreOn September 1, the Centers for Medicare and Medicaid Services will announce the first 10 Medicare Part D drugs chosen for the Medicare Drug Price Negotiation Program. This is the first of many steps in the wrong direction, all created by the Inflation Reduction Act that was signed into law a year ago.
Read MoreIn an impressive new ad, “Protecting America’s Future,” the American Edge Project advocates for online freedom in the United States and condemns foreign countries that abuse their power using the internet.
Read MoreExpanding on the Inflation Reduction Act of last year, the SMART Prices Act would aim to cap the prices of medicine. This may sound helpful, however, any short-term benefits would be overshadowed quickly by long-term damage.
Read MoreThe deceptively named legislation Lowering Drug Costs for American Families Act was recently introduced by House Democratic Health Committee leaders. The legislation was introduced by Frank Pallone, Jr. (D-NJ), Richard Neal (D-MA), and Robert “Bobby” Scott (D-VA), and it is meant to be an addition to the Inflation Reduction Act (IRA).
Read MoreTAPP submitted comments to the Centers for Medicare & Medicaid Services to oppose a proposed rule change regarding prescription drugs. Particularly, the rule change that would result in an annual survey, conducted by the federal government, on American life science companies.
Read MoreTAPP recently signed onto a letter addressed to leadership in the U.S. Senate Committee on Agriculture, Nutrition and Forestry and the U.S. House Committee on Agriculture to urge them to reform the U.S. sugar program.
Read MoreThe House Judiciary Committee held a hearing today on the Oversight of the Federal Trade Commission (FTC). The hearing focused on FTC chair Lina Khan and FTC’s market overreach and centralization of power.
Read MoreTAPP recently submitted comments to the Senate HELP Committee in response to Senator Bernie Sanders’s request for public input on the proposed “reasonable pricing” scheme.
Read MoreResearch firm Vital Transformation modeled the impacts of government mandated drug pricing schemes currently proposed as the Smart Prices Act (SPA). The SPA would impose government price setting for certain Medicare drugs at only five years after initial FDA approval.
Read More